Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Efecto del interferón gamma como tratamiento para la inmunosupresión posagresiva en unidades de cuidados intensivos, un ensayo controlado aleatorizado, doble ciego, bayesiano versus placebo (INFINITY)

10 de noviembre de 2026 actualizado por: Assistance Publique - Hôpitaux de Paris

The vast majority of serious clinical situations leading to intensive care (septic shock, polytrauma, acute cerebral aggression, major surgery) are characterized by significant systemic inflammation. Recently, the existence of a common immune response pattern to acute aggression has been demonstrated, and with it the existence of a phenomenon known as post-aggressive immunosuppression (PAIS).

Descripción general del estudio

Descripción detallada

The vast majority of serious clinical situations leading to intensive care (septic shock, polytrauma, acute cerebral aggression, major surgery) are characterized by significant systemic inflammation. Recently, the existence of a common immune response pattern to acute aggression has been demonstrated, and with it the existence of a phenomenon known as post-aggressive immunosuppression (PAIS).

This immunological adaptation, initially implemented as a host defense mechanism to protect against an overwhelming systemic reaction, can, if prolonged, lead to multiple complications resulting in significant delayed morbidity and mortality. Diagnosis is based on the use of immuno-inflammatory biomarkers, the most widely studied of which is monocyte expression of major histocompatibility complex type II molecules (mHLA-DR).

We have recently confirmed that PAIS can affect all types of patients admitted to the intensive care unit, but mainly occurs in the most severe patients. We also showed that the occurrence of PAIS was strongly associated with the subsequent occurrence of secondary infection and excess mortality.

Currently, there is no treatment with proven efficacy for PAIS, but several drugs have been shown to restore leukocyte function in-vitro. Several teams have reported the use of immunostimulatory molecules in patients with treatment failure, with a good safety profile and encouraging results. We believe that earlier treatment of patients with proven PAIS could improve their clinical outcome.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

170

Fase

  • Fase 2
  • Fase 3

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Copia de seguridad de contactos de estudio

Ubicaciones de estudio

      • Limoges, Francia, 87000
        • Reclutamiento
        • Dr Francois Bruno
        • Contacto:
      • Nancy, Francia
        • Reclutamiento
        • Pr Antoine Kimmoun
        • Contacto:
      • Paris, Francia
        • Reclutamiento
        • Pr Dépret
        • Contacto:
          • Pr Dépret François, Professor
          • Número de teléfono: +33 01 42 49 95 70
          • Correo electrónico: francois.depret@aphp.fr
      • Paris, Francia, 75010
        • Reclutamiento
        • Pr Benjamin Chousterman
        • Contacto:
      • Paris, Francia, 75013
        • Reclutamiento
        • Pr Constantin Michel
        • Contacto:
      • Paris, Francia
        • Reclutamiento
        • Pr Megarbane
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Patient ≥ 18 years old
  • SOFA score for first 24 hours post-admission ≥ 6
  • Mechanically ventilated at the time of inclusion (non-invasive ventilation (NIV) and high-flow nasal oxygen excluded)
  • mHLA-DR< 8,000 AB/C measured between the 5th and 10th day after admission to the intensive care unit
  • Patient affiliated to a social security scheme
  • Written informed consent from a parent, relative or trusted person. If there is no parent, relative or trusted person, the patient may be included under an emergency procedure and consent to continue will be obtained as soon as possible

Exclusion Criteria:

  • Patient with estimated life expectancy of less than 3 months
  • Patients with a predicted remaining stay in intensive care < 72 hours
  • Patients with an expected prolonged duration of mechanical ventilation: comatose or vegetative patients (admission for severe stroke with Glasgow score < 8, patient resuscitated from an arterial stroke,) patients with tracheotomy for ENT problems, patients suffering from muscular disease (e.g. myopathy), patients on long-term mechanical ventilation
  • Pregnant or breast-feeding women
  • Contraindication of Imukin (hypersensitivity to interferon gamma-1b or known hypersensitivity to related products, such as another interferon)
  • Patients on immunosuppressive therapy, including long-term corticosteroid therapy (>2.5mg/d prednisone equivalent)
  • Patients with preexisting severe hepatic( Grade C cirrhosis ) or preexisting kidney failure requiring dialysis
  • Patient included in another interventional study (excluding RIPH2 cases not involving prolonged mechanical ventilation)
  • People under court protection and protected adults

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Triple

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: interferon gamma-1b injection

Patients randomized to the experimental arm will receive :

Recombinant human interferon gamma-1b 2 X 106 IU, injectable solution. Subcutaneous injection every 24 hours for 3 consecutive days (3 total injections)

Comparador de placebos: Placebo injection

Patients randomized to the placebo arm will receive saline injectable solution. Subcutaneous injection every 24 hours for 3 consecutive days (3 total injections)

Patients randomized to the placebo arm will receive saline injectable solution. Subcutaneous injection every 24 hours for 3 consecutive days (3 total injections)

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
number of days alive without mechanical ventilation
Periodo de tiempo: on Day 28 after drug administration

number of days alive without mechanical ventilation on day 28 after randomization or on discharge from intensive care if this occurs before the 28th day

on Day 28 after drug administration

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Evaluate the efficacy of IFNy in correcting PAIS-defining biological abnormalities (re-ascension of mHLA-DR above 8,000 AB/C) between patients treated with recombinant interferon gamma 1-b versus placebo
Periodo de tiempo: Day 1 to Day 7 and at Day 28 post randomization

Evolution of mHLA-DR measured at Day 0, Day 1, Day 2, Day 3, Day 7 and Day 28 or at discharge from intensive care if earlier (Day 0 corresponding to the day of inclusion in the study) between patients treated with recombinant interferon gamma 1-b versus placebo.

Day 1 to Day 7 and at Day 28 post randomization
Evaluate, depending on the randomization arm, the kinetics of plasma inflammatory parameters between patients treated with recombinant interferon gamma 1-b versus placebo
Periodo de tiempo: Day 0, Day 3 and at Day 7 post randomization

Evolution of inflammation markers (IL-1, IL-2, IL-6, IL-8, TNFa, etc.) measured in plasma at Day 0, Day 3 and Day 7, or at discharge from intensive care if it occurs before (Day 0 corresponding to the day of inclusion in the study) between patients treated with recombinant interferon gamma 1-b versus placebo

Day 0, Day 3 and at Day 7 post randomization
mortality at Day 28 and Day 90 after randomization
Periodo de tiempo: Day 28 and Day 90 after randomization

Mortality rate at Day 28 and Day 90 after randomization between patients treated with recombinant interferon gamma 1-b versus placebo

Day 28 and Day 90 after randomization
incidence of nosocomial infections during intensive care unit stay
Periodo de tiempo: from Day 0 to Day 28 (or the discharge from intensive care)

The incidence of nosocomial infections during an ICU stay between patients treated with recombinant interferon gamma 1-b versus placebo

from Day 0 to Day 28 (or the discharge from intensive care)
number of days alive whithout antibiotic
Periodo de tiempo: Day 28 after drug administration

Number of days alive without antibiotic assessed on day 28 after randomization between patients treated with recombinant interferon gamma 1-b versus placebo

Day 28 after drug administration
length of stay in intensive care between patients
Periodo de tiempo: from Day 0 to Day 28 (or the discharge from intensive care)

Number of days in intensive care between patients treated with recombinant interferon gamma 1-b versus placebo

from Day 0 to Day 28 (or the discharge from intensive care)
- Compare organ failure score (SOFA) kinetics between patients treated with recombinant interferon gamma 1-b versus placebo
Periodo de tiempo: From inclusion to Day 7

Kinetics of SOFA score assessed at inclusion and during the 7 days following inclusion between patients treated with recombinant interferon gamma 1-b versus placebo

From inclusion to Day 7
Evaluate, depending on the randomization arm, the transcriptomic profile of circulating peripheral blood mononuclear cells count between patients treated with recombinant interferon gamma 1-b versus placebo
Periodo de tiempo: Day 0, Day 3 and Day 7 after randomization

Evolution of the transcriptomic profile of circulating peripheral blood mononuclear cells (PBMCs) using scRNAseq analysis measured at Day 0, Day 3 and Day 7 or upon discharge from intensive care if this occurs earlier.

Day 0, Day 3 and Day 7 after randomization
Evaluate, depending on the randomization arm the leucocyte count between patients treated with recombinant interferon gamma 1-b versus placebo
Periodo de tiempo: Day 0 to Day 7 and at Day 28 post randomization

Evolution and kenetics of the leucocyte count measured at Day 0, Day 1, Day 2, Day 3, Day 7 and Day 28 or at discharge from intensive care if earlier (Day 0 corresponding to the day of inclusion in the study) between patients treated with recombinant interferon gamma 1-b versus placebo

Day 0 to Day 7 and at Day 28 post randomization

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Silla de estudio: Benjamin Chousterman, Professor, APHP(ASSISTANCE PUBLIQUE DES HOPITAUX DE PARIS

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

24 de febrero de 2026

Finalización primaria (Estimado)

1 de marzo de 2029

Finalización del estudio (Estimado)

1 de mayo de 2029

Fechas de registro del estudio

Enviado por primera vez

12 de noviembre de 2024

Primero enviado que cumplió con los criterios de control de calidad

15 de noviembre de 2024

Publicado por primera vez (Actual)

19 de noviembre de 2024

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

12 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

10 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

INDECISO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir